Skip to main content
Fig. 9 | Journal of Nanobiotechnology

Fig. 9

From: Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer

Fig. 9

Effects of Nano-DOX and DOX on the emission of DAMPs in 4T1 cells. a, b FACS analysis of immunostaining of HSP90 and CRT in in vitro 4T1 cells treated with Nano-DOX or DOX. Representative FACS histograms are presented in Additional file 1: Fig. S5. c Bioilluminance assay of ATP released from in vitro 4T1 cells treated with Nano-DOX or DOX. d ELISA assay of HMGB1 released from in vitro 4T1 cells treated with Nano-DOX or DOX. e Confocal microscopy of HSP90 immunostaining in in vitro 4T1 cells treated with Nano-DOX or DOX. f Confocal microscopy of CRT immunostaining in in vitro 4T1 cells treated with Nano-DOX or DOX. g Immunohistochemical staining of HSP90, CRT and HMGB1 in 4T1 tumor xenografts at the end of 3-week treatment of Nano-DOX or DOX. Duration of Nano-DOX or DOX treatment was 24 h for the in vitro cell experiments. In FACS analysis, geometric means were used to quantify fluorescence intensity. Values were mean ± SD (n = 3, *p < 0.05, **p < 0.01)

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us